Novo's obesity drug achieves significant weight loss in late-stage trial | Retatrutide News

Novo Nordisk's new obesity drug demonstrated a 25% weight loss in women in a late-stage trial. This finding is relevant for GLP-1 agonist research, incl...
Weight Loss · October 26, 2026